Condition: Acute Lymphoblastic Leukemia, in Relapse · Acute Lymphoblastic Leukemia With Failed Remission · Sponsor: Instituto do Cancer do Estado de São Paulo
This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.
This description comes directly from the study's public registry record.
Graziela S Silva · 551138934677 · graziela.sasilva@hc.fm.usp.br
Bruna Moraes, MSc · 551126628112 · pesquisa.hematologia@hc.fm.usp.br
Always discuss trial participation with your own doctor first.
| Instituto do Cancer do Estado de Sao Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06034561